Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Join Barchart Premier and get daily trading ideas and historical data downloads. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Rhythm Pharmaceuticals Inc (RYTM)

Rhythm Pharmaceuticals Inc (RYTM)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 5,662,268
  • Shares Outstanding, K 63,621
  • Annual Sales, $ 130,130 K
  • Annual Income, $ -260,600 K
  • EBIT $ -173 M
  • EBITDA $ -171 M
  • 60-Month Beta 2.26
  • Price/Sales 31.85
  • Price/Cash Flow N/A
  • Price/Book 218.65

Options Overview Details

View History
  • Implied Volatility 60.95% ( -4.14%)
  • Historical Volatility 93.79%
  • IV Percentile 76%
  • IV Rank 31.57%
  • IV High 112.19% on 07/08/25
  • IV Low 37.30% on 05/16/25
  • Put/Call Vol Ratio 7.43
  • Today's Volume 1,837
  • Volume Avg (30-Day) 917
  • Put/Call OI Ratio 3.31
  • Today's Open Interest 15,919
  • Open Int (30-Day) 7,715

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 14 analysts offering recommendations.
Earnings Estimates - Current Qtr 06/30/25
See More
  • Average Estimate -0.65
  • Number of Estimates 13
  • High Estimate -0.49
  • Low Estimate -0.87
  • Prior Year -0.55
  • Growth Rate Est. (year over year) -18.18%

Price Performance

See More
Period Period Low Period High Performance
1-Month
60.70 +45.99%
on 06/18/25
94.80 -6.52%
on 07/10/25
+21.25 (+31.54%)
since 06/10/25
3-Month
55.31 +60.22%
on 05/14/25
94.80 -6.52%
on 07/10/25
+30.79 (+53.24%)
since 04/10/25
52-Week
40.61 +118.22%
on 08/05/24
94.80 -6.52%
on 07/10/25
+44.24 (+99.68%)
since 07/10/24

Most Recent Stories

More News
RYTM Stock Rises on Upbeat Acquired Hypothalamic Obesity Study Data

Shares of Rhythm Pharmaceuticals RYTM were up 36.6% yesterday after it reported positive top-line data from a phase II study evaluating the investigational oral melanocortin-4 receptor (MC4R) agonist,...

AMRN : 17.30 (-0.17%)
RYTM : 88.44 (-0.63%)
KROS : 14.43 (+0.77%)
ALKS : 30.83 (+2.84%)
Rhythm Pharmaceuticals, Inc. Announces Pricing of Upsized Public Offering of Common Stock

RYTM : 88.44 (-0.63%)
Rhythm Pharmaceuticals, Inc. Announces Proposed Public Offering of Common Stock

RYTM : 88.44 (-0.63%)
Rhythm Pharmaceuticals Announces Oral MC4R Agonist Bivamelagon Achieved Statistically Significant, Clinically Meaningful BMI Reductions in Placebo-controlled Phase 2 Trial in Acquired Hypothalamic Obesity

RYTM : 88.44 (-0.63%)
Rhythm Pharmaceuticals To Announce Topline Results from Phase 2 Trial Evaluating Oral MC4R Agonist Bivamelagon in Acquired Hypothalamic Obesity

RYTM : 88.44 (-0.63%)
Rhythm Pharmaceuticals Announces Three Late-breaking Data Abstracts Accepted for Presentation at ENDO 2025

RYTM : 88.44 (-0.63%)
Rhythm Pharmaceuticals Announces New Data Presentations on Patients with Acquired or Congenital Hypothalamic Obesity (N=35) Treated with Setmelanotide for up to Nine Months in French Early-access Program

RYTM : 88.44 (-0.63%)
Rhythm Pharmaceuticals Reports First Quarter 2025 Financial Results and Business Update

RYTM : 88.44 (-0.63%)
Rhythm Pharmaceuticals Announces Participation in Upcoming Investor Conferences

RYTM : 88.44 (-0.63%)
Rhythm Pharmaceuticals to Report First Quarter 2025 Financial Results on Wednesday, May 7, 2025

RYTM : 88.44 (-0.63%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 100% Buy with a Strongest short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

The market is approaching overbought territory. Be watchful of a trend reversal.

See More Share

Business Summary

Rhythm Pharmaceuticals, Inc. is a biopharmaceutical company. It focused on the development and commercialization of peptide therapeutics for the treatment of rare genetic deficiencies which result in life-threatening metabolic disorders. The Company's product candidate principally consists of setmelanotide,...

See More

Key Turning Points

3rd Resistance Point 107.74
2nd Resistance Point 98.39
1st Resistance Point 93.70
Last Price 88.44
1st Support Level 79.66
2nd Support Level 70.31
3rd Support Level 65.62

See More

52-Week High 94.80
Last Price 88.44
Fibonacci 61.8% 74.10
Fibonacci 50% 67.71
Fibonacci 38.2% 61.31
52-Week Low 40.61

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar